Monday, December 30, 2019

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer

AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer The drug is now the only approved medicine in biomarker-selected patients with advanced pancreatic cancer.

from Moneycontrol Business News https://ift.tt/35awRrv

No comments:

Post a Comment

IREDA shares rise 1.1% as board announces meeting date for fund raise via QIP

IREDA shares rose by 1.1% to Rs 209.50 on news of a board meeting set for January 23, 2025, to approve fund-raising via Qualified Institutio...